Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-130 + HS-110 in advanced solid tumors
NCT04116710Phase 1Completed
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Oct 2019
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-130 in solid tumor (advanced stage), sponsored by NightHawk Biosciences, Inc. Primary endpoint: Dose Limiting Toxicity at 1 month. Started Oct 2019; status: completed.
02
Drugs
HS-130
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04116710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116710.